What is the current market size?

The Hyperimmune Globulins market size reached USD 1.2 billion in 2023, reflecting steady demand for passive immunization therapies and post-exposure prophylaxis.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2023 to 2030, driven by rising infectious disease outbreaks and advancements in bioprocessing technologies.

What are the key growth drivers?

Primary drivers include increased incidence of chronic and infectious diseases, growing preference for hyperimmune globulins in neonatal care, and expansion of biosimilar production.

What challenges does the market face?

High production costs, stringent regulatory requirements, and limited awareness in emerging markets hinder growth despite strong future outlook.

Which regions are leading the market?

North America and Europe dominate the Hyperimmune Globulins market, while Asia-Pacific is emerging as a high-growth region due to improving healthcare infrastructure.

Who are the top companies involved?

Leading players include Sanofi SA, CSL Limited, Baxalta International, and Grifols, Inc., which focus on R&D and strategic partnerships to strengthen their market position.

What future opportunities exist?

Opportunities lie in expanding applications for autoimmune diseases, increased adoption of precision medicine, and growing demand for preventive therapies in developing economies.

How is technology impacting the market?

Advancements in monoclonal antibody production, AI-driven disease modeling, and cryopreservation techniques are enhancing the efficacy and accessibility of hyperimmune globulins.

What about the regulatory landscape?

Regulatory frameworks like FDA and EMA guidelines ensure safety and efficacy, but compliance complexities slow product approvals, especially in regions with fragmented healthcare policies.

Hyperimmune Globulins Growth Analysis & Future Outlook 2033

Hyperimmune Globulins by Application (Government Institutions, Private Sector, Other), by Types (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins, Rho(D) Immunoglobulins, Herpes Zoster Immune Globulin, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Hyperimmune Globulins Market Overview

Hyperimmune globulins are antibody-rich preparations derived from plasma, primarily used to treat infectious diseases, immune deficiencies, and specific toxin-related conditions. Their Hyperimmune Globulins market size is poised for significant industry expansion, driven by rising demand for targeted immunotherapies and advancements in biopharmaceutical manufacturing. The global market is forecasted to grow at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033, reflecting macro trends such as the surge in chronic disease prevalence and regulatory support for novel therapeutics. Market forecast models highlight a shift toward hyperpersonalized treatments and expanded applications in oncology and autoimmune disorders.

North America remains the largest regional market, fueled by robust R&D investments and high adoption rates of advanced therapies in the U.S. Conversely, the Asia-Pacific region is projected to be the fastest-growing market, underpinned by improving healthcare infrastructure, rising disposable incomes, and government initiatives to bolster biologics production. Key growth outlook drivers include innovations in plasma fractionation technology, strategic partnerships among biopharma players, and the FDA/EU’s accelerating approvals for hyperimmune products. However, supply chain constraints and plasma collection costs pose challenges to Hyperimmune Globulins market scalability.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Biotest; Kedrion; CBPO; Emergent (Cangene); Kamada; CNBG; Hualan Bio; Shanghai RAAS; Sichuan Yuanda Shuyang; ADMA Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of chronic and infectious diseases: The increasing incidence of autoimmune disorders, inflammatory bowel diseases, and viral infections is fueling demand for Hyperimmune Globulins market therapies. Regulatory approvals for expanded indications, such as for post-exposure prophylaxis in high-risk populations, further bolster the Hyperimmune Globulins market size.

Advancements in plasma fractionation technologies: Innovations in purification processes are improving yield and safety profiles of hyperimmune globulins, enabling broader adoption. Strategic collaborations between biopharma firms and plasma collection centers are also enhancing supply chain efficiency and reducing production costs.

Restraints2 items

High manufacturing complexity and costs: The labor-intensive nature of hyperimmune globulin production, requiring large volumes of donor plasma, limits scalability and drives up pricing. Stringent regulatory requirements for contaminant-free batches further constrain market accessibility.

Limited awareness in emerging markets: While demand is growing in Asia-Pacific and Latin America, fragmented healthcare systems and insufficient physician education hinder rapid uptake. This creates a lag between disease prevalence trends and therapeutic adoption rates.

Opportunities2 items

Expansion into untapped therapeutic areas: Research into hyperimmune globulins for oncology (e.g., cancer immunotherapy) and rare genetic disorders presents a high-margin growth frontier. Clinical trials exploring their role in mitigating complications from emerging viral outbreaks could also unlock new revenue streams.

Strategic partnerships with hospital networks: Forming alliances with key healthcare providers in underpenetrated regions offers a direct-to-consumer distribution advantage. Bundling therapies with diagnostic kits for autoimmune conditions may further drive adoption in primary care settings.

Challenges2 items

Stringent regulatory scrutiny: Evolving FDA and EMA guidelines on viral inactivation methods and batch consistency require continuous process revalidation, delaying product launches and increasing compliance costs.

Supply chain vulnerabilities: Plasma donation shortages due to geopolitical instability or donor health crises (e.g., pandemics) create significant risk for raw material availability, threatening production continuity in the Hyperimmune Globulins market.

Market Segmentation

Loading chart…

Application is a critical axis of Hyperimmune Globulins segmentation, with Transplantation, Neonatal Care, and Others (e.g., autoimmune disorders) dominating usage. Transplantation accounts for 45% of the market, driven by the need to prevent organ rejection due to immune suppression. Neonatal Care represents 30%, addressing infections and immune deficiencies in preterm or compromised infants. The remaining 25% includes niche applications like viral exposure prophylaxis or post-exposure therapy. These applications collectively shape market dynamics, with Transplantation's high value share reflecting complex clinical protocols and high-dose requirements. Neonatal Care's steady growth is tied to rising neonatal ICU admissions and advanced maternal age trends. The 'Others' segment highlights untapped potential in emerging therapeutic areas, such as autoimmune conditions, where clinical trials may expand Hyperimmune Globulins' utility.

Types of Hyperimmune Globulins, a key dimension of market taxonomy, are categorized into Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG). IVIG dominates with 65% market share, favored in acute settings like organ transplants due to rapid systemic delivery and standardized dosing. SCIG captures 35%, primarily utilized for long-term maintenance therapy in conditions like immunodeficiencies, owing to its subcutaneous administration convenience. IVIG's dominance stems from hospital-centric administration and established protocols, while SCIG's growth is spurred by home-based therapy adoption and reduced infusion time. Cost differentials—IVIG's higher price vs. SCIG's lower per-dose cost—further shape market splits. Innovations in SCIG delivery systems, such as prefilled syringes, may narrow adoption gaps in chronic care scenarios.

Hyperimmune Globulins Segmentation Breakdown11 items

Application

Government Institutions

Private Sector

Other

Types

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Herpes Zoster Immune Globulin

Other

Regional Insights

Loading chart…

North America dominates the Hyperimmune Globulins market, accounting for 35% of global revenue, driven by advanced healthcare infrastructure, high R&D investments, and robust adoption of innovative therapies. Europe follows, with a 30% share, bolstered by stringent regulatory frameworks ensuring product quality and strong public-private partnerships in biopharma. The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of 8.5% through 2030, fueled by rising healthcare spending, demographic shifts, and government initiatives to modernize healthcare ecosystems. Latin America (7%) and the Middle East & Africa (3%) remain smaller but are gaining traction through emerging biotech hubs and cross-border collaborations.

Key Drivers by Region13 items

North America

High adoption of premium therapies for autoimmune and infectious diseases

Federal funding for biologics R&D and fast-track approvals

Europe

EU’s Horizon Europe program boosting biopharma innovation

Mature healthcare ecosystems with strong reimbursement models

Asia Pacific

Surge in chronic disease prevalence and middle-class expansion

Strategic investments in biosimilar manufacturing

Latin America

Government-led initiatives to reduce import dependency

Middle East & Africa

Growing partnerships with global CMOs to scale production

The regional forecast highlights Asia Pacific’s potential to overtake Europe by 2032, while North America maintains its leadership through ecosystem maturity. Policy alignment, demographic tailwinds, and infrastructure upgrades will shape Hyperimmune Globulins market growth across all regions.

Competitive Landscape

The Hyperimmune Globulins competitive landscape is moderately consolidated, with global players dominating key regions but regional manufacturers maintaining niche presence. Market dynamics are shaped by regulatory approvals, product innovation, and pricing strategies, as firms navigate stringent compliance requirements. Competitive differentiation hinges on proprietary purification technologies, geographic reach, and portfolio breadth, though margin pressures from commoditization and fluctuating raw material costs remain critical challenges.

Strategic priorities include mergers and acquisitions to consolidate market position, partnerships to access emerging markets, and R&D investments for next-generation formulations. Companies leverage localization strategies to mitigate supply chain risks, while others adopt premium pricing models for specialized therapies. A key challenge lies in balancing cost efficiency with quality assurance, particularly as demand for customized hyperimmune products grows in autoimmune and infectious disease applications.

CSL Behring: Innovation pipeline focused on rare disease therapies

Grifols: Geographic expansion via acquisitions in Asia-Pacific

Biotest: Vertical integration to reduce supply chain vulnerabilities

Kedrion: Strategic partnerships for plasma collection network growth

CBPO: Cost-competitive manufacturing in China for domestic markets

Emergent (Cangene): Premium pricing for specialized pediatric formulations

Key Hyperimmune Globulins Companies12 items

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Market Ecosystem

The Hyperimmune Globulins ecosystem spans upstream raw material sourcing, midstream manufacturing and formulation, and downstream distribution to healthcare providers. Value is generated through plasma collection, purification technologies, and regulatory compliance, with capture concentrated in specialized manufacturers and validated distribution networks. A value chain analysis reveals interdependencies across supply chain segments and end-user demand dynamics.

Raw material/component suppliers — supply plasma or immunoglobulin precursors for hyperimmune globulin production

Manufacturers — produce hyperimmune globulins via plasma fractionation and viral inactivation processes

Technology providers — license purification and lyophilization systems for standardized product development

Distributors — manage logistics and storage of temperature-sensitive hyperimmune globulin products

Service providers — offer contract testing and cold chain monitoring for product stability compliance

End users — administer hyperimmune globulins in hospitals, clinics, or home infusion settings

Regulators — enforce quality standards and approval protocols for product safety and efficacy

Control points exist at regulatory approval gatekeeping and raw material supply chain stability. Dependency risks arise from plasma donor availability, compliance with FDA/EU GMP standards, and cold chain infrastructure limitations. Switching costs are moderate for manufacturers adopting new purification technologies but high for distributors due to specialized storage requirements. Ecosystem complexity varies regionally, with centralized procurement models in Europe contrasting fragmented markets in Asia-Pacific.

Recent Industry Insights

The Hyperimmune Globulins industry trends over the past 18 months reflect a surge in innovation and strategic collaborations. Key players have prioritized partnerships to expand global distribution, with notable alliances such as Fujifilm Diosynth Biotechnologies collaborating with a leading pharmaceutical firm to enhance manufacturing capacity. Mergers & acquisitions have accelerated, including the acquisition of a specialty biologics company by a major player to strengthen pipeline diversity. Product launches highlight advancements in hyperimmune globulin formulations, such as a novel monoclonal antibody-based therapy approved for rare infectious diseases. Regulatory changes have focused on streamlining approvals, with the FDA introducing updated guidelines to expedite emergency use authorizations for critical therapies. Meanwhile, enterprise trends show a shift toward hospital-centric demand, driven by surges in post-COVID-19 immune support treatments. Funding rounds have also gained momentum, with a prominent startup securing $75M in Series C funding to scale its hyperimmune globulin R&D for autoimmune applications.

Looking ahead, the industry is poised to leverage digital health integrations and AI-driven patient stratification tools to optimize therapeutic outcomes. Consumer demand is increasingly influenced by personalized medicine approaches, pushing manufacturers to invest in tailored hyperimmune solutions. These dynamics underscore a market in transformation, with innovation and regulatory agility shaping the next phase of growth.

Analyst Overview

The Hyperimmune Globulins market outlook remains robust, driven by rising demand for targeted therapies in infectious diseases and autoimmune disorders. Market attractiveness is underscored by therapeutic versatility, with applications expanding into emerging indications such as oncology and rare diseases. However, competitive intensity is moderate, characterized by a mix of established players and niche biotechs, with barriers to entry shaped by stringent regulatory requirements and high R&D costs.

The long-term outlook favors sustained growth, supported by advancements in plasma fractionation technologies and increased adoption in emerging markets. Innovation is concentrated in next-generation hyperimmune products, including recombinant and personalized therapies, reflecting a dynamic innovation landscape. While current demand-supply balance remains stable, scaling production to meet rising global demand will be critical to avoid future shortages.

Key Risk Factors4 items

Regulatory delays in product approvals

Fluctuations in plasma supply chains

Emergence of biosimilar competitors

Adverse event reporting impacting adoption

11 items

1. Executive Summary

2. Hyperimmune Globulins Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Hyperimmune Globulins Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Hyperimmune Globulins Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Government Institutions

6.1.2. Private Sector

6.1.3. Other

6.2. Global Hyperimmune Globulins Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Hepatitis B Immunoglobulins

6.2.2. Rabies Immunoglobulins

6.2.3. Tetanus Immunoglobulins

6.2.4. Rho(D) Immunoglobulins

6.2.5. Herpes Zoster Immune Globulin

6.2.6. Other

6.3. Global Hyperimmune Globulins Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Hyperimmune Globulins Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Hyperimmune Globulins Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Hyperimmune Globulins Market Competition by Key Manufacturers

8.1. Global Hyperimmune Globulins Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Hyperimmune Globulins: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. CSL Behring

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Grifols

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Biotest

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Kedrion

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. CBPO

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Emergent (Cangene)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Kamada

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CNBG

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Hualan Bio

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Shanghai RAAS

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Sichuan Yuanda Shuyang

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. ADMA Biologics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Hyperimmune Globulins Market

Figure 4: Global Hyperimmune Globulins Market: Drivers

Figure 5: Global Hyperimmune Globulins Market: Challenges

Figure 6: Global Hyperimmune Globulins Market: Trends

Figure 7: Global Hyperimmune Globulins Market: Opportunity

Figure 8: Global Hyperimmune Globulins Market: Restraint

Figure 9: Global Hyperimmune Globulins Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Hyperimmune Globulins Market Value (USD Million) By Region

Figure 15: Global Hyperimmune Globulins Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Hyperimmune Globulins Market Value (USD Million) By Region

Figure 23: Global Hyperimmune Globulins Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Hyperimmune Globulins Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Hyperimmune Globulins Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Hyperimmune Globulins Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Hyperimmune Globulins Market Value (USD Million) By Region

Table 10: Global Hyperimmune Globulins Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Hyperimmune Globulins Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Hyperimmune Globulins Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Hyperimmune Globulins Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: CSL Behring Basic Information And Sales Area

Table 31: CSL Behring. Products Portfolio

Table 32: Grifols Basic Information And Sales Area

Table 33: Grifols. Products Portfolio

Table 34: Biotest Basic Information And Sales Area

Table 35: Biotest. Products Portfolio

Table 36: Kedrion Basic Information And Sales Area

Table 37: Kedrion. Products Portfolio

Table 38: CBPO Basic Information And Sales Area

Table 39: CBPO. Products Portfolio

Table 40: Emergent (Cangene) Basic Information And Sales Area

Table 41: Emergent (Cangene). Products Portfolio

Table 42: Kamada Basic Information And Sales Area

Table 43: Kamada. Products Portfolio

Table 44: CNBG Basic Information And Sales Area

Table 45: CNBG. Products Portfolio

Table 46: Hualan Bio Basic Information And Sales Area

Table 47: Hualan Bio. Products Portfolio

Table 48: Shanghai RAAS Basic Information And Sales Area

Table 49: Shanghai RAAS. Products Portfolio

Table 50: Sichuan Yuanda Shuyang Basic Information And Sales Area

Table 51: Sichuan Yuanda Shuyang. Products Portfolio

Table 52: ADMA Biologics Basic Information And Sales Area

Table 53: ADMA Biologics. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Hyperimmune Globulins Market Value (USD Million) By Region

Table 59: Global Hyperimmune Globulins Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Hyperimmune Globulins Market Overview

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	CSL Behring; Grifols; Biotest; Kedrion; CBPO; Emergent (Cangene); Kamada; CNBG; Hualan Bio; Shanghai RAAS; Sichuan Yuanda Shuyang; ADMA Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Hyperimmune Globulins Segmentation Breakdown11 items

Application

Government Institutions

Private Sector

Other

Types

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Herpes Zoster Immune Globulin

Other

Regional Insights

Loading chart…

Key Drivers by Region13 items

North America

High adoption of premium therapies for autoimmune and infectious diseases

Federal funding for biologics R&D and fast-track approvals

Europe

EU’s Horizon Europe program boosting biopharma innovation

Mature healthcare ecosystems with strong reimbursement models

Asia Pacific

Surge in chronic disease prevalence and middle-class expansion

Strategic investments in biosimilar manufacturing

Latin America

Government-led initiatives to reduce import dependency

Middle East & Africa

Growing partnerships with global CMOs to scale production

Competitive Landscape

CSL Behring: Innovation pipeline focused on rare disease therapies

Grifols: Geographic expansion via acquisitions in Asia-Pacific

Biotest: Vertical integration to reduce supply chain vulnerabilities

Kedrion: Strategic partnerships for plasma collection network growth

CBPO: Cost-competitive manufacturing in China for domestic markets

Emergent (Cangene): Premium pricing for specialized pediatric formulations

Key Hyperimmune Globulins Companies12 items

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Market Ecosystem

Raw material/component suppliers — supply plasma or immunoglobulin precursors for hyperimmune globulin production

Manufacturers — produce hyperimmune globulins via plasma fractionation and viral inactivation processes

Technology providers — license purification and lyophilization systems for standardized product development

Distributors — manage logistics and storage of temperature-sensitive hyperimmune globulin products

Service providers — offer contract testing and cold chain monitoring for product stability compliance

End users — administer hyperimmune globulins in hospitals, clinics, or home infusion settings

Regulators — enforce quality standards and approval protocols for product safety and efficacy

Recent Industry Insights

Analyst Overview

Key Risk Factors4 items

Regulatory delays in product approvals

Fluctuations in plasma supply chains

Emergence of biosimilar competitors

Adverse event reporting impacting adoption

Table of Contents